Biological and Clinical Aspects of the Treatment of Schizophrenia and Related Disorders: Second Edition
A special issue of Healthcare (ISSN 2227-9032).
Deadline for manuscript submissions: 30 May 2024 | Viewed by 1272
Special Issue Editor
2. Neurosciences Institute, Universitat Autònoma de Barcelona, CIBERSAM, 08221 Terrassa, Spain
Interests: schizophrenia; psychosis; affective disorder; psychoneuroendocrinology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
For several decades, the dopamine hypothesis of schizophrenia has appeared to explain the neurobiology of the disorder, the biological underpinnings of treatment response, and the primary mechanism of action in antipsychotic responses. However, a significant volume of research suggests that other biological and neurotransmitter systems are implicated. Patients with schizophrenia exhibit marked positive and negative symptoms, as well as present cognitive symptoms and affective domains. Although antipsychotics are considered the gold standard, preclinical and clinical studies report that almost one-third of patients with schizophrenia fail to respond to standard antipsychotic treatment.
The present Special Issue aims to summarize new evidence pertaining to the role of biological systems interacting with dopamine and other neurotransmitters, and their implication in the occurrence of psychotic symptoms and treatment responses. The role of stress hormones and other hormonal compounds in the clinical presentation (phenotype) and response to treatment will also be explored. Articles presenting evidence regarding the effectiveness of pharmacological and non-pharmacological interventions in treating schizophrenia and related disorders are also welcome, with a special emphasis on treatments targeting emotions and cognitive symptoms. The impact of physical health on psychotic symptoms and vice versa is also a topic of interest in psychotic populations.
Dr. Jose Antonio Monreal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- psychosis
- neurobiology
- clinical phenotypes
- treatment outcomes
